• Roche's Genentech reported interim Phase III results showing sefaxersen significantly reduced urinary protein versus placebo in adults with IgA nephropathy.
• Results were presented at the American Society of Nephrology's Kidney Week 2026; treatment was well tolerated, with no new safety signals.
• The investigational monthly injection's trial will continue to assess kidney function over two years; data will be shared with health authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261023402425) on October 23, 2026, and is solely responsible for the information contained therein.